Pharmacovigilance in developing countries (part I): importance and challenges.
The thalidomide disaster was the significant historical event that acted as a catalyst for pharmacovigilance activity. Following this event developed countries initiated drug monitoring systems that evolved and now extend their scope to broader drug-related safety issues; however, this was not the case in developing countries. Pharmacovigilance is still a relatively new concept with low priority in developing countries although various issues are raising concerns that magnify the need for systems to monitor post marketing drug safety in these countries. This article analyzes the barriers to introducing robust pharmacovigilance systems in developing countries.
['Elshafie|Shaimaa|S|http://orcid.org/0000-0001-7279-4418', 'Zaghloul|Iman|I|', 'Roberti|Anne Marie|AM|']
D016907:Adverse Drug Reaction Reporting Systems D003906:Developing Countries D004335:Drug and Narcotic Control D064420:Drug-Related Side Effects and Adverse Reactions D005006:Ethnicity D033161:Government Regulation D054624:Health Status Disparities D054625:Healthcare Disparities D006801:Humans D061214:Patient Safety D060735:Pharmacovigilance D011050:Policy Making D018570:Risk Assessment D012307:Risk Factors
Pharmacovigilance Developing countries Drug safety Adverse drug reactions Post marketing monitoring